Therefore, KMO inhibitors seem to be a valuable therapeutic solution in the management of patients with AD, HD, and PD to ameliorate symptoms associated with 3-HKYN, 3-HAA, and QA accumulation in the brain. The gene discussed is KMO; the disease is Parkinson disease.